Skip to main content
    T

    Takeda Pharmaceutical Co Ltd ADR (TAK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE

    $21.59
    +0.16 (+0.77%)

    Market Cap: $68.47B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Takeda Pharmaceutical Co Ltd ADR (TAK) Financials: Revenue, Profit and Cash Flow

    Updated Oct 29, 2026. Financial statements from company filings, amounts in JPY.

    Takeda Pharmaceutical Co Ltd ADR reported revenue of JPY 4.78T for the fiscal year ended Mar 31, 2026, up 4.3% from the year before. That year, net income was JPY 203.33B with a net margin of 4.3%, operating cash flow was JPY 1.04T and free cash flow was JPY 626.77B. The quarter ended Sep 30, 2026 had revenue of JPY 1.19T and net income of JPY 192.43B.

    Revenue and Margins

    The operating margin was 12.0% in the fiscal year ended Mar 2026. Over the 9 years to Mar 2026, revenue grew from JPY 1.73T, a compound annual rate of 12.0%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Mar 20264.78T+4.3%51.1%12.0%4.3%
    Mar 20254.58T+7.5%65.5%7.5%2.4%
    Mar 20244.26T+5.9%66.4%5.0%3.4%
    Mar 20234.03T+12.8%69.1%12.2%7.9%
    Mar 20223.57T+11.6%69.0%12.9%6.4%
    Mar 20213.20T-2.8%68.9%15.9%11.8%
    Mar 20203.29T+56.9%66.9%3.1%1.3%
    Mar 20192.10T+18.5%68.5%9.8%5.2%
    Mar 20181.77T+2.2%72.0%13.7%10.6%
    Mar 20171.73TN/A67.7%9.0%6.6%
    Annual, fiscal years ended Mar 2017 to Mar 2026

    Income Statement

    In the fiscal year ended Mar 2026, net income rose 88.4% from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Revenue4.78T4.58T4.26T4.03T3.57T3.20T3.29T2.10T1.77T1.73T
    Cost of revenue2.34T1.58T1.43T1.24T1.11T994.31B1.09T659.69B495.92B558.75B
    Gross profit2.44T3.00T2.83T2.78T2.46T2.20T2.20T1.44T1.27T1.17T
    Research and development716.69B730.23B729.92B633.33B526.09B455.83B492.38B368.30B325.44B312.30B
    Operating income573.04B342.59B214.07B490.50B460.84B509.27B100.41B204.97B241.79B155.87B
    Net income203.33B107.93B144.07B317.02B230.06B376.00B44.24B109.13B186.89B114.94B
    EBITDA1.38T1.21T1.23T1.28T1.18T983.72B671.90B464.22B359.96B296.88B
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue1.19T1.22T1.11T1.21T1.11T1.11T1.05T1.14T1.18T1.21T1.05T1.11T
    Gross profit795.00B813.22B543.81B660.35B732.74B722.01B671.30B727.25B781.73B821.04B663.54B731.71B
    Operating income205.32B201.42B47.54B194.06B69.00B184.57B-74.90B66.94B184.25B166.33B-10.07B104.91B
    Net income192.43B113.20B-24.77B105.51B-11.80B124.24B-103.20B23.79B92.05B95.25B-3.02B105.72B
    Last 12 quarters

    Balance Sheet

    As of Mar 2026, total debt of JPY 4.88T exceeded cash and equivalents by 4.29T.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Total assets15.52T14.25T15.11T13.96T13.18T12.91T12.82T13.87T4.11T4.36T
    Current assets3.10T2.52T2.56T2.40T2.59T2.71T2.47T3.05T1.08T1.26T
    Cash and equivalents597.63B385.11B457.80B533.53B849.70B966.22B637.61B702.09B294.52B319.45B
    Total liabilities7.71T7.31T7.83T7.60T7.49T7.74T8.09T8.71T2.09T2.41T
    Short-term debt514.38B548.94B367.25B339.60B203.99B22.15B586.82B984.95B18.00M545.03B
    Long-term debt4.37T3.97T4.48T4.04T4.14T4.61T4.51T4.77T985.64B599.86B
    Shareholder equity7.81T6.94T7.27T6.35T5.68T5.17T4.72T5.16T2.00T1.89T
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets15.27T15.66T15.52T15.42T14.47T14.00T14.25T15.11T14.57T16.23T15.11T14.22T
    Total liabilities7.85T8.10T7.71T7.77T7.34T7.14T7.31T7.69T7.65T8.43T7.83T7.48T
    Cash and equivalents418.53B460.98B597.63B655.38B681.49B350.01B385.11B494.13B859.01B804.27B457.80B288.36B
    Shareholder equity7.42T7.56T7.81T7.65T7.13T6.87T6.94T7.42T6.92T7.80T7.27T6.74T
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Mar 2026, free cash flow was 60.3% of operating cash flow. Dividends came to 49.8% of it.

    Annual

    Line itemMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
    Operating cash flow1.04T1.06T716.34B977.16B1.12T1.01T669.75B328.48B377.85B261.36B
    Capital expenditures414.66B379.63B480.73B633.69B186.04B236.47B217.71B134.11B128.26B112.03B
    Free cash flow626.77B677.56B235.61B343.47B937.07B774.46B452.04B194.37B249.59B149.34B
    Dividends paid311.90B302.50B287.19B279.42B283.67B283.36B282.58B142.95B141.89B141.69B
    Investing cash flow-369.14B-367.06B-463.86B-607.10B-198.13B393.53B292.12B-2.84T-93.34B-655.69B
    Financing cash flow-496.82B-751.42B-354.42B-709.15B-1.07T-1.09T-1.01T2.95T-326.23B289.90B
    Fiscal years ended Mar 2017 to Mar 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow257.18B127.62B74.53B373.25B378.23B215.42B222.16B383.76B280.96B170.30B278.59B146.45B
    Capital expenditures44.54B53.81B64.39B222.37B52.83B75.07B92.72B56.65B92.45B153.49B64.33B77.12B
    Free cash flow212.65B73.81B10.13B150.88B325.40B140.35B129.44B327.11B188.51B16.81B214.26B69.33B
    Last 12 quarters

    Frequently Asked Questions About TAK

    What is Takeda Pharmaceutical Co Ltd ADR's annual revenue?

    Takeda Pharmaceutical Co Ltd ADR reported revenue of JPY 4.78T for the fiscal year ended Mar 31, 2026.

    How fast is Takeda Pharmaceutical Co Ltd ADR's revenue growing?

    Revenue was up 4.3% for the fiscal year ended Mar 31, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 5.9%.

    Is Takeda Pharmaceutical Co Ltd ADR profitable?

    Yes. Takeda Pharmaceutical Co Ltd ADR reported net income of JPY 203.33B for the fiscal year ended Mar 31, 2026, with a net margin of 4.3%.

    How much free cash flow does TAK generate?

    For the fiscal year ended Mar 31, 2026, operating cash flow of JPY 1.04T minus capital expenditures of JPY 414.66B produced free cash flow of JPY 626.77B.

    How much debt does Takeda Pharmaceutical Co Ltd ADR have?

    The balance sheet dated Mar 31, 2026 reported long-term debt of JPY 4.37T, short-term debt of JPY 514.38B and cash and equivalents of JPY 597.63B.